697300-73-5

Basic information

• Product Name: 3-BROMO-5-IODOPYRIDIN-2-AMINE
• Synonyms: 3-BROMO-5-IODOPYRIDIN-2-AMINE;2-Amino-3-bromo-5-iodopyridine;3-Bromo-5-iodo-2-pyridinamine;3-BroMo-5-iodo-pyridin-2-ylaMine;3-Bromo-5-iodo-2-aminopyridine;2-Pyridinamine, 3-bromo-5-iodo-;CL020
• CAS NO: 697300-73-5
• Molecular Formula: C₅H₄BrIN₂
• Molecular Weight: 298.91
• Mol File: 697300-73-5.mol
• Article Data: 5

Chemical Properties

• Melting Point: 106-110℃
• Boiling Point: 315.7 °C at 760 mmHg
• Flash Point: 144.8 °C
• Appearance: /
• Density: 2.426
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 2.15±0.49(Predicted)
• CAS DataBase Reference: 3-BROMO-5-IODOPYRIDIN-2-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-5-IODOPYRIDIN-2-AMINE(697300-73-5)
• EPA Substance Registry System: 3-BROMO-5-IODOPYRIDIN-2-AMINE(697300-73-5)

Safety Data

• Hazardous Substances Data: 697300-73-5(Hazardous Substances Data)

Usage

General Description

3-Bromo-5-iodopyridin-2-amine is a specialized chemical compound, primarily used in sophisticated research fields, including organic synthesis and drug discovery. The presence of functional groups such as the bromo and iodo substituents and the amino group makes it useful for certain types of chemical reactions. Its molecular formula is C5H3BrIN2 and the molecular weight is 282.90 g/mol. Like all chemicals, it must be handled with care due to the risk of eye irritation, skin irritation, or respiratory irritation. Safety measures should be followed as recommended by Material Safety Data Sheets (MSDS).

Upstream product

• 20511-12-0 2-amino-5-iodopyridine 
• 13534-99-1 2-Amino-3-bromopyridine 

Downstream Products

• 697300-72-4 3-bromo-2-fluoro-5-iodopyridine 
• 1416315-10-0 C₁₂H₉BrN₂O₂ 
• 1416315-09-7 (4-(6-amino-5-bromopyridin-3-yl)phenyl)(morpholino)methanone 
• 1416315-14-4 C₂₂H₁₉F₃N₄O₂ 
• 1314882-87-5 {4-[2-amino-3-(4-(trifluoromethyl)phenyl)pyridin-5-yl]phenyl}(morpholino)methanone 
• 1416315-15-5 C₂₃H₂₂F₃N₅O 
• 1416315-17-7 C₂₂H₂₀F₃N₅O 
• 1416315-18-8 C₂₃H₂₁F₃N₄O 
• 1416315-16-6 C₂₄H₂₃F₃N₄O 
• 1416315-11-1 (4-(6-amino-5-bromopyridin-3-yl)phenyl)(4-methylpiperazin-1-yl)methanone 
• 1416315-12-2 (4-(6-amino-5-bromopyridin-3-yl)phenyl)(N-Bocpiperazin-1-yl)methanone 
• 1416315-13-3 C₂₇H₂₈F₃N₅O₃ 
• 1415694-74-4 4-[8-(5,6-Dimethoxy-pyridin-2-ylamino)-[1,2,4]triazolo[1,5-a]pyridin-6-yl]-N-(2-pyridin-4-yl-ethyl)-benzamide 
• 1415694-66-4 4-{3-[8-(5,6-Dimethoxy-pyridin-2-ylamino)-[1,2,4]triazolo[1,5-a]pyridin-6-yl]-benzoylamino}-2-methoxy-benzoic acid 

Relevant articles and documents

MULTI-SUBSTITUTED PYRIDONE DERIVATIVES AND MEDICAL USE THEREOF

The present invention relates to multi-substituted pyridone derivatives and therapeutic use thereof. In particular, the present invention relates to a compound of formula (I), a preparation method therefor, a pharmaceutical composition comprising the same, as well as use thereof as a tyrosine kinase inhibitor, in particular, use thereof in treating a disease associated with tyrosine kinase activity. Each substituent in the formula (I) is defined as in the specification.

TRIAZOLOPYRIDINE COMPOUNDS

The present invention relates to the use of novel triazolopyridine derivatives of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

5-Substituted Derivatives of 6-Halogeno-3-((2-(S)-azetidinyl)methoxy)pyridine and 6-Halogeno-3-((2-(S)-pyrrolidinyl)methoxy)pyridine with Low Picomolar Affinity for α4β2 Nicotinic Acetylcholine Receptor and Wide Range of Lipophilicity: Potential Probes for Imaging with Positron Emission Tomography

Potential positron emission tomography (PET) ligands with low picomolar affinity at the nicotinic acetylcholine receptor (nAChR) and with lipophilicity (log D) ranging from - 1.6 to +1.5 have been synthesized. Most members of the series, which are derivatives of 5-substituted-6-halogeno-A-85380, exhibited a higher binding affinity at α4β2-nAChRs than epibatidine. An analysis, by molecular modeling, revealed an important role of the orientation of the additional heterocyclic ring on the binding affinity of the ligands with nAChRs. The existing nicotinic pharmacophore models do not accommodate this finding. Two compounds of the series, 6-[18F]fluoro-5-(pyridin-3-yl)-A-85380 ([18F]31) and 6-chloro-3-((2-(S)-azetidinyl)methoxy)-5-(2-[ 18F]fluoropyridin-5-yl)pyridine) ([18F]35), were radiolabeled with 18F. Comparison of PET data for [18F]31 and 2-[18F]FA shows the influence of lipophilicity on the binding potential. Our recent PET studies with [18F]35 demonstrated that its binding potential values in Rhesus monkey brain were ca. 2.5 times those of 2-[18F]FA. Therefore, [18F]35 and several other members of the series, when radiolabeled, will be suitable for quantitative imaging of extrathalamic nAChRs.